HLA-identical renal transplant recipients: immunosuppression, long-term complications, and survival.
Peddi
V R
VR
University of Cincinnati Medical Center, Cincinnati, Ohio, USA. ram.peddi@uc.edu
Weiskittel
P
P
Alexander
J W
JW
Woodle
E S
ES
First
M R
MR
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D044383:Black People; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival / Q000502:physiology*; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D009679:Nuclear Family; D009820:Ohio; D011183:Postoperative Complications / Q000145:classification*; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D044465:White People; D001741:Black or African American
D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone